ImmunoVaccine Technologies, Inc. (IMV Inc.)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, ImmunoVaccine Technologies, Inc. (IMV Inc.) sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

ImmunoVaccine Technologies, Inc. (IMV Inc.): 6 sponsored US clinical trials, 1 recruiting.

ImmunoVaccine Technologies, Inc. (IMV Inc.) sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Microsatellite Instability High, with 1 trials.

Upper-quartile sponsor footprint

ImmunoVaccine Technologies, Inc. (IMV Inc.) sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 2

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617
ACTIVE NOT RECRUITING Phase 2

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352
TERMINATED Phase 2

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

NCT05243524
COMPLETED Phase 1

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

NCT03332576
COMPLETED Phase 1

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

NCT01416038
COMPLETED Phase 1

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Therapeutic Areas

Microsatellite Instability High 1
Relapsed Diffuse Large B-cell Lymphoma 1
Peritoneal Cancer 1
Refractory Diffuse Large B-Cell Lymphoma 1
Fallopian Tube Cancer 1
Hepatocellular Carcinoma 1
Bladder Cancer 1
Non-Small Cell Lung Cancer 1
Ovarian Cancer 1
Epithelial Ovarian Cancer 1

What is open in the ImmunoVaccine Technologies, Inc. (IMV Inc.) pipeline

1 recruiting of 6 indexed (17% open); 3 completed (50%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Microsatellite Instability High (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

ImmunoVaccine Technologies, Inc. (IMV Inc.): open-pipeline peers nationwide

Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

ImmunoVaccine Technologies, Inc. (IMV Inc.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%20%40%60%80% Total trials Recruiting share ImmunoVaccine Technologies, Inc. (IMV Inc.)23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAdageneAgendiaAkamis BioAngiodynamics
ImmunoVaccine Technologies, Inc. (IMV Inc.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ImmunoVaccine Technologies, Inc. (IMV Inc.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ImmunoVaccine Technologies, Inc. (IMV Inc.) page

6 registered trials is a research-attention snapshot, not an endorsement of ImmunoVaccine Technologies, Inc. (IMV Inc.) or any single study.

  • 1 of ImmunoVaccine Technologies, Inc. (IMV Inc.)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Microsatellite Instability High is the condition ImmunoVaccine Technologies, Inc. (IMV Inc.) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Microsatellite Instability High trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ImmunoVaccine Technologies, Inc. (IMV Inc.) pipeline card: 6 registered trials from official public datasets.Report a data error.